AbbVie Inc. Total non-current assets

Total non-current assets of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total non-current assets growth rates and interactive chart. The sum of all non-current or long-term assets.

Highlights and Quick Summary

  • Total non-current assets for the quarter ending June 29, 2021 was $122 Billion (a -1.58% decrease compared to previous quarter)
  • Year-over-year quarterly Total non-current assets decreased by -3.66%
  • Annual Total non-current assets for 2020 was $126 Billion (a 219.2% increase from previous year)
  • Annual Total non-current assets for 2019 was $39.6 Billion (a -6.63% decrease from previous year)
  • Annual Total non-current assets for 2018 was $42.4 Billion (a -14.44% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total non-current assets of AbbVie Inc.

Most recent Total non-current assetsof ABBV including historical data for past 10 years.

Interactive Chart of Total non-current assets of AbbVie Inc.

AbbVie Inc. Total non-current assets for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $121,973.0 $123,932.0
2020 $126,392.0 $126,612.0 $128,274.0 $39,441.0 $126,392.0
2019 $39,596.0 $39,275.0 $42,042.0 $42,356.0 $39,596.0
2018 $42,407.0 $47,699.0 $47,796.0 $48,898.0 $42,407.0
2017 $49,563.0 $49,910.0 $50,032.0 $50,117.0 $49,563.0
2016 $49,912.0 $50,336.0 $50,420.0 $37,098.0 $49,912.0
2015 $36,736.0 $36,920.0 $36,978.0 $11,291.0 $36,736.0
2014 $11,432.0 $10,899.0 $11,251.0 $11,328.0 $11,432.0
2013 $11,350.0 $11,709.0 $12,248.0 $12,246.0 $11,350.0
2012 $11,654.0 $11,799.24 $11,716.59 $12,210.51 $11,654.0
2011 $12,167.0 $12,167.0
2010 $16,660.56 $12,916.21

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.